Nephros (NEPH) Competitors $1.94 +0.06 (+2.91%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. MBOT, SRTS, NSPR, FONR, MLSS, ZYXI, INO, ICCM, CTSO, and VANIShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Microbot Medical (MBOT), Sensus Healthcare (SRTS), InspireMD (NSPR), FONAR (FONR), Milestone Scientific (MLSS), Zynex (ZYXI), Inovio Pharmaceuticals (INO), IceCure Medical (ICCM), Cytosorbents (CTSO), and Vivani Medical (VANI). These companies are all part of the "medical equipment" industry. Nephros vs. Microbot Medical Sensus Healthcare InspireMD FONAR Milestone Scientific Zynex Inovio Pharmaceuticals IceCure Medical Cytosorbents Vivani Medical Microbot Medical (NASDAQ:MBOT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Do insiders and institutionals believe in MBOT or NEPH? 16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 5.4% of Microbot Medical shares are owned by insiders. Comparatively, 4.1% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, MBOT or NEPH? Nephros has higher revenue and earnings than Microbot Medical. Nephros is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMicrobot MedicalN/AN/A-$10.74M-$0.74-3.36Nephros$14.16M1.47-$1.58M-$0.09-21.77 Which has more risk and volatility, MBOT or NEPH? Microbot Medical has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Is MBOT or NEPH more profitable? Microbot Medical has a net margin of 0.00% compared to Nephros' net margin of -6.86%. Nephros' return on equity of -11.39% beat Microbot Medical's return on equity.Company Net Margins Return on Equity Return on Assets Microbot MedicalN/A -218.30% -158.17% Nephros -6.86%-11.39%-8.30% Do analysts recommend MBOT or NEPH? Microbot Medical currently has a consensus target price of $9.00, suggesting a potential upside of 261.45%. Nephros has a consensus target price of $5.00, suggesting a potential upside of 155.23%. Given Microbot Medical's higher possible upside, equities analysts clearly believe Microbot Medical is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Microbot Medical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in MBOT or NEPH? Microbot Medical received 336 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 70.79% of users gave Microbot Medical an outperform vote while only 43.33% of users gave Nephros an outperform vote. CompanyUnderperformOutperformMicrobot MedicalOutperform Votes34970.79% Underperform Votes14429.21% NephrosOutperform Votes1343.33% Underperform Votes1756.67% Does the media refer more to MBOT or NEPH? In the previous week, Microbot Medical had 8 more articles in the media than Nephros. MarketBeat recorded 8 mentions for Microbot Medical and 0 mentions for Nephros. Microbot Medical's average media sentiment score of 0.53 beat Nephros' score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media. Company Overall Sentiment Microbot Medical Positive Nephros Neutral SummaryMicrobot Medical beats Nephros on 9 of the 15 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.77M$4.04B$5.30B$7.35BDividend YieldN/A39.51%5.12%4.30%P/E Ratio-21.7727.6821.8017.80Price / Sales1.4747.06379.9697.74Price / CashN/A51.0838.2634.64Price / Book2.455.816.443.98Net Income-$1.58M$67.09M$3.21B$247.73M7 Day Performance2.57%1.97%2.88%1.81%1 Month Performance28.88%-4.84%-8.63%-6.98%1 Year Performance-1.56%14.47%11.46%1.29% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros1.7297 of 5 stars$1.96+3.7%$5.00+155.2%-1.6%$20.77M$14.16M-21.7730MBOTMicrobot Medical1.9513 of 5 stars$2.28+2.2%$9.00+294.7%+176.7%$79.22MN/A-2.8520High Trading VolumeSRTSSensus Healthcare2.4942 of 5 stars$4.79+3.9%$13.00+171.4%+41.2%$79.01M$41.81M11.9840Gap DownNSPRInspireMD2.2861 of 5 stars$2.60+1.6%$4.75+82.7%+17.2%$77.19M$7.01M-3.4750High Trading VolumeFONRFONAR0.9692 of 5 stars$12.07-0.2%N/A-25.8%$74.87M$101.57M10.50480Short Interest ↑Negative NewsMLSSMilestone Scientific2.0355 of 5 stars$0.91+1.6%$1.25+36.8%+58.0%$71.19M$8.88M-13.0630Analyst ForecastNews CoverageGap DownZYXIZynex3.0388 of 5 stars$2.20+0.9%$10.25+365.9%-81.9%$66.50M$192.35M14.67770Analyst ForecastGap DownINOInovio Pharmaceuticals3.263 of 5 stars$1.77+9.9%$12.20+589.3%-84.3%$64.90M$217,756.00-0.44320Analyst UpgradeShort Interest ↑ICCMIceCure Medical1.6225 of 5 stars$1.16+3.1%$2.50+115.5%-12.8%$64.38M$3.29M-4.0060Negative NewsCTSOCytosorbents1.7749 of 5 stars$0.99+1.9%$4.67+371.4%+30.4%$61.88M$35.59M-2.75220Gap DownVANIVivani Medical2.815 of 5 stars$1.04+2.0%$4.00+284.6%-42.4%$61.60MN/A-2.3120Analyst ForecastShort Interest ↑Gap Up Related Companies and Tools Related Companies Microbot Medical Competitors Sensus Healthcare Competitors InspireMD Competitors FONAR Competitors Milestone Scientific Competitors Zynex Competitors Inovio Pharmaceuticals Competitors IceCure Medical Competitors Cytosorbents Competitors Vivani Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NEPH Stock Free NEPH Stock Alerts